Debt to Equity Ratio Chart

View Debt to Equity Ratio for CDNA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 0.0452
March 31, 2026 0.0781
December 31, 2025 0.0864
September 30, 2025 0.0888
June 30, 2025 0.089
March 31, 2025 0.0798
December 31, 2024 0.075
September 30, 2024 0.1097
June 30, 2024 0.1188
March 31, 2024 0.1286
December 31, 2023 0.131
September 30, 2023 0.0893
June 30, 2023 0.0898
March 31, 2023 0.0899
December 31, 2022 0.0905
September 30, 2022 0.0914
June 30, 2022 0.043
March 31, 2022 0.0446
December 31, 2021 0.0458
September 30, 2021 0.046
June 30, 2021 0.0441
March 31, 2021 0.0459
December 31, 2020 0.0654
September 30, 2020 0.069
June 30, 2020 0.0726
Date Value
March 31, 2020 0.1904
December 31, 2019 0.0333
September 30, 2019 0.0242
June 30, 2019 0.026
March 31, 2019 0.0237
December 31, 2018 0.0044
September 30, 2018 0.3128
June 30, 2018 0.4762
March 31, 2018 0.3125
December 31, 2017 -5.555
September 30, 2017 -116.45
June 30, 2017 2.869
March 31, 2017 2.218
December 31, 2016 1.263
September 30, 2016 0.7722
June 30, 2016 0.9407
March 31, 2016 0.7747
December 31, 2015 0.5365
September 30, 2015 0.4659
June 30, 2015 0.4305
March 31, 2015 0.3985
December 31, 2014 0.278
September 30, 2014 0.3121
June 30, 2014 -12.94
March 31, 2014 -0.9038

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Natera, Inc. 0.1309
Caris Life Sciences, Inc. 0.7645
Myriad Genetics, Inc. 0.6927
BioRestorative Therapies, Inc. 0.0114
Exagen, Inc. 2.264